Does the media prefer LBRX or ARQT?

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for LB Pharmaceuticals and 6 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.16 beat LB Pharmaceuticals' score of 1.06 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, LBRX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A Telix Pharmaceuticals $803.79M 4.32 -$7.12M N/A N/A

Is LBRX or TLX more profitable?

Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A Telix Pharmaceuticals N/A N/A N/A

Does the media favor LBRX or TLX?

In the previous week, Telix Pharmaceuticals had 6 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 7 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.06 beat Telix Pharmaceuticals' score of 0.02 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer OGN or LBRX?

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for LB Pharmaceuticals and 3 mentions for Organon & Co.. LB Pharmaceuticals' average media sentiment score of 1.06 beat Organon & Co.'s score of 0.48 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral LB Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, GPCR or LBRX?

Structure Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A

Is GPCR or LBRX more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% LB Pharmaceuticals N/A N/A N/A

Does the media favor GPCR or LBRX?

In the previous week, Structure Therapeutics had 2 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 9 mentions for Structure Therapeutics and 7 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.06 beat Structure Therapeutics' score of 1.03 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LBRX or RCUS?

In the previous week, Arcus Biosciences had 9 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 16 mentions for Arcus Biosciences and 7 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.06 beat Arcus Biosciences' score of 0.38 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

LB Pharmaceuticals (LBRX) Competitors

$35.01 +0.39 (+1.13%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$36.02 +1.01 (+2.88%)

As of 07/24/2026 07:34 PM Eastern

Compare

LBRX vs. ARQT, TLX, OGN, GPCR, and RCUS

Should you buy LB Pharmaceuticals stock or one of its competitors? MarketBeat compares LB Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LB Pharmaceuticals include Arcutis Biotherapeutics (ARQT), Telix Pharmaceuticals (TLX), Organon & Co. (OGN), Structure Therapeutics (GPCR), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does LB Pharmaceuticals compare to Arcutis Biotherapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

LB Pharmaceuticals currently has a consensus price target of $40.43, indicating a potential upside of 15.48%. Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 24.31%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

LB Pharmaceuticals has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. LB Pharmaceuticals' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Arcutis Biotherapeutics has higher revenue and earnings than LB Pharmaceuticals. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Arcutis Biotherapeutics	$415.62M	8.23	-$16.14M	-$0.03	N/A

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for LB Pharmaceuticals and 6 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.16 beat LB Pharmaceuticals' score of 1.06 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LB Pharmaceuticals beats Arcutis Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Telix Pharmaceuticals (NASDAQ:TLX) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

LB Pharmaceuticals presently has a consensus target price of $40.43, indicating a potential upside of 15.48%. Telix Pharmaceuticals has a consensus target price of $20.40, indicating a potential upside of 99.61%. Given Telix Pharmaceuticals' higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Telix Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Telix Pharmaceuticals	$803.79M	4.32	-$7.12M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Telix Pharmaceuticals had 6 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 13 mentions for Telix Pharmaceuticals and 7 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.06 beat Telix Pharmaceuticals' score of 0.02 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

LB Pharmaceuticals and Telix Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Organon & Co. has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.16B	0.58	$187M	$0.93	14.54
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 15.71%. LB Pharmaceuticals has a consensus price target of $40.43, indicating a potential upside of 15.48%. Given LB Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe LB Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Organon & Co. has a net margin of 3.99% compared to LB Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
LB Pharmaceuticals	N/A	N/A	N/A

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for LB Pharmaceuticals and 3 mentions for Organon & Co.. LB Pharmaceuticals' average media sentiment score of 1.06 beat Organon & Co.'s score of 0.48 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Organon & Co. beats LB Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Structure Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

Structure Therapeutics currently has a consensus price target of $110.55, suggesting a potential upside of 125.05%. LB Pharmaceuticals has a consensus price target of $40.43, suggesting a potential upside of 15.48%. Given Structure Therapeutics' higher probable upside, research analysts plainly believe Structure Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

LB Pharmaceuticals' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
LB Pharmaceuticals	N/A	N/A	N/A

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Structure Therapeutics had 2 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 9 mentions for Structure Therapeutics and 7 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.06 beat Structure Therapeutics' score of 1.03 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LB Pharmaceuticals beats Structure Therapeutics on 7 of the 13 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Arcus Biosciences?

LB Pharmaceuticals (NASDAQ:LBRX) and Arcus Biosciences (NYSE:RCUS) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Arcus Biosciences had 9 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 16 mentions for Arcus Biosciences and 7 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.06 beat Arcus Biosciences' score of 0.38 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Arcus Biosciences	$236M	15.14	-$353M	-$3.18	N/A

92.9% of Arcus Biosciences shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LB Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. LB Pharmaceuticals' return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Arcus Biosciences	-156.36%	-68.97%	-35.27%

LB Pharmaceuticals currently has a consensus price target of $40.43, indicating a potential upside of 15.48%. Arcus Biosciences has a consensus price target of $36.40, indicating a potential upside of 28.12%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

LB Pharmaceuticals beats Arcus Biosciences on 8 of the 15 factors compared between the two stocks.

Get LB Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LBRX vs. The Competition

Export

Metric	LB Pharmaceuticals	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$992.80M	$3.11B	$7.26B	$12.26B
Dividend Yield	N/A	15.20%	40.99%	9.79%
P/E Ratio	-20.24	13.16	23.62	23.71
Price / Sales	N/A	2,745.01	171.18	76.09
Price / Cash	N/A	25.90	165.01	59.64
Price / Book	2.94	8.60	12.77	6.07
Net Income	-$25.20M	-$34.07M	$120.21M	$331.84M
7 Day Performance	11.46%	-0.13%	-0.94%	-1.53%
1 Month Performance	12.94%	-0.41%	-1.97%	-2.46%
1 Year Performance	N/A	9.87%	9.83%	13.66%

LB Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LBRX LB Pharmaceuticals	2.0966 of 5 stars	$35.01 +1.1%	$40.43 +15.5%	N/A	$992.80M	N/A	N/A	16	Analyst Forecast
ARQT Arcutis Biotherapeutics	3.454 of 5 stars	$27.53 -3.4%	$34.00 +23.5%	+82.1%	$3.56B	$376.07M	N/A	150	Positive News
TLX Telix Pharmaceuticals	4.4421 of 5 stars	$10.51 +0.5%	$20.40 +94.1%	-26.4%	$3.55B	$803.79M	N/A	1,184	Short Interest Increase Gap Down
OGN Organon & Co.	2.2213 of 5 stars	$13.51 -0.1%	$11.40 -15.6%	+34.4%	$3.55B	$6.22B	14.52	10,000	News Coverage Positive News
GPCR Structure Therapeutics	2.3054 of 5 stars	$46.98 -3.1%	$110.55 +135.3%	+168.9%	$3.45B	N/A	N/A	136	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LBRX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. ARQT, TLX, OGN, GPCR, and RCUS

How does LB Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Summary

How does LB Pharmaceuticals compare to Structure Therapeutics?

Summary

How does LB Pharmaceuticals compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. ARQT, TLX, OGN, GPCR, and RCUS

How does LB Pharmaceuticals compare to Arcutis Biotherapeutics?

Do analysts prefer LBRX or ARQT?

Is LBRX or ARQT more profitable?

Which has preferable earnings & valuation, LBRX or ARQT?

Does the media prefer LBRX or ARQT?

Summary

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Do analysts rate LBRX or TLX?

Which has better valuation and earnings, LBRX or TLX?

Is LBRX or TLX more profitable?

Does the media favor LBRX or TLX?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Which has preferable earnings & valuation, OGN or LBRX?

Do institutionals and insiders believe in OGN or LBRX?

Do analysts recommend OGN or LBRX?

Is OGN or LBRX more profitable?

Does the media prefer OGN or LBRX?

Summary

How does LB Pharmaceuticals compare to Structure Therapeutics?

Which has better earnings and valuation, GPCR or LBRX?

Do analysts prefer GPCR or LBRX?

Is GPCR or LBRX more profitable?

Do institutionals & insiders hold more shares of GPCR or LBRX?

Does the media favor GPCR or LBRX?

Summary

How does LB Pharmaceuticals compare to Arcus Biosciences?

Does the media refer more to LBRX or RCUS?

Which has better valuation & earnings, LBRX or RCUS?

Do institutionals & insiders have more ownership in LBRX or RCUS?

Is LBRX or RCUS more profitable?

Do analysts recommend LBRX or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools